Eli Lilly Q3 2026 Results: Price, Volume and the Guidance Split Explained
A financial reading of the Eli Lilly Q3 2026 results: price versus volume, one-time items, the EPS cut and what guidance implies for Q4.
Read More
FDA ICH M15 Guidance: What Sponsors and Regulatory Teams Should Take From the Webinar
What the FDA ICH M15 guidance means for sponsors: preparation steps, global alignment and the questions the webinar leaves open.
Baby Memorial Hospital DeepInfinity AI Partnership: The Business Case for One AI Partner
The Baby Memorial Hospital DeepInfinity AI partnership tests one-vendor hospital AI. The operational case, the risks and what is undisclosed.
Molecular Partners Workforce Reduction 2026: What the 44% Cut Means for Cash and Strategy
What the Molecular Partners workforce reduction 2026 means for cash, costs and the radiotherapy pipeline, and what is still unreported.
Geron IMpactMF Trial Discontinued: What It Means for the Company and the Sector
What the Geron IMpactMF trial discontinued means for strategy, Rytelo and the Q3 results due on 4 November 2026.
Biogen Q3 2026 Results: Revenue Up 11%, but EPS Falls and Guidance Is Only Trimmed Up
A financial reading of the Biogen Q3 2026 results: revenue up 11%, EPS down, and a guidance low end lifted after a July cut.
Nucelion Pandorum Partnership: What the CDMO Deal Means for India’s Advanced Therapies
What the Nucelion Pandorum partnership means for India’s CDMO sector, PRIP-backed research and investigational eye therapies.
Vera Health Series A Funding: Investor View of a Free-to-Clinicians AI Search Engine
What the Vera Health Series A funding says about the business model of a free clinical AI tool, and which claims remain unverified.
UK GP Websites Outage October 2026: Resilience Lessons for Healthcare IT Buyers
What the UK GP websites outage October 2026 teaches healthcare IT buyers about supplier risk, data custody and continuity planning.